CJC 1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life.
CJC 1295 has the following amino acid sequence:
Ac-Ser-Tyr-dSer-Lys-Pro-Asp-Asn-Ala-NH2
The following is a breakdown of the amino acid sequence of CJC 1295:
- Ac: Acetyl group
- Ser: Serine
- Tyr: Tyrosine
- dSer: D-serine
- Lys: Lysine
- Pro: Proline
- Asp: Aspartic acid
- Asn: Asparagine
- Ala: Alanine
- NH2: Amide group
The acetyl group at the beginning of the sequence protects CJC 1295 from degradation by enzymes. The D-serine residue at position 3 increases the stability of CJC 1295 and slows down its clearance from the bloodstream.
CJC 1295 is a linear peptide, meaning that the amino acids are linked together in a straight line. This is in contrast to cyclic peptides, where the amino acids are linked together in a ring.
Linear peptides are generally more stable than cyclic peptides, but they are also more susceptible to degradation by enzymes. The acetyl group at the beginning of the sequence protects CJC 1295 from degradation by enzymes.
CJC 1295 is a relatively small peptide, with only 8 amino acids. However, it is very potent in stimulating growth hormone release. This is because CJC 1295 binds to the same receptors on the pituitary gland as GHRH.
When CJC 1295 binds to these receptors, it stimulates the release of growth hormone from the pituitary gland. Growth hormone is a hormone that plays a vital role in many bodily functions, including growth and development, muscle and bone repair, and metabolism.
CJC 1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life. CJC 1295 is a linear peptide with 8 amino acids. It is a very potent stimulator of growth hormone release.
Potential uses of CJC 1295
CJC 1295 is being investigated for its potential use in a variety of conditions, including:
- Growth hormone deficiency
- Aging
- Alzheimer’s disease
- Parkinson’s disease
- Multiple sclerosis
- Spinal cord injury
- Traumatic brain injury
- Sarcopenia
- Cachexia
- Athletic performance enhancement
However, it is important to note that CJC 1295 is not yet approved by the FDA for any use. More research is needed to determine its safety and efficacy in humans.
